

### **Remarks**

Applicants request entry of the amendments and reconsideration of the application.

Applicants have amended the specification at page 34 (line 12) to correct the SEQ ID NO as requested by the Examiner and to correct typographical errors made in an earlier amendment. Applicants have amended claim 32 by deleting the phrase "capable of specific interaction with parkin" and adding the term "human" before "PAP1 sequence." Support for this amendment can be found throughout the specification, specifically at page 3 line 26 to page 4 line 7. Claims 32-33, 39, 53 and 59 are pending after entry of the amendment.

No new matter enters by these amendments.

Claim 39 has been allowed.

### **Initial Comments**

Applicants request an Examiner Interview to discuss the amendment to the claims and the outstanding rejections. Applicants' representative will contact the Examiner approximately one (1) month after the filing of this response to arrange a convenient time.

### **Rejection under 35 U.S.C. § 112, First Paragraph**

Claims 32, 33, 38, 53, 59 and 63-65 stand rejected under 35 U.S.C. § 112, first paragraph, for allegedly containing subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the art that the inventors had possession of the claimed invention. Applicants respectfully disagree.

Applicants note that claims 38 and 63-65 have been canceled. Also, claim 32, upon which the remaining rejected claims depend, has been amended to recite "a peptide compound having an amino acid sequence of at least 95% identity to the full length *human* PAP1 sequence." The specification clearly describes the human PAP1 sequence of SEQ ID NO: 2 as well as variants that are 95% homologous to SEQ ID NO: 2, such as SEQ ID NO: 15.

Applicants submit that the specification clearly shows to one of skill in the art that applicants were in possession of the subject matter claimed in claims 32, 33, 39, 53 and 59

at the time of filing. Applicants respectfully request reconsideration and withdrawal of this rejection.

Claims 32, 38, 53, 59 and 63-65 also stand rejected under 35 U.S.C. § 112, first paragraph, for allegedly failing to enable a person of skill in the art to make and use the invention.

Applicants note that claim 32, upon which the remaining rejected claims depend, has been amended to delete the phrase "specific interaction with parkin." The claim recites "a peptide compound having an amino acid sequence of at least 95% identity to the full length human PAP1 sequence of SEQ ID NO: 2." The examiner has stated that the specification is enabling for the PAP1 sequence of SEQ ID NO: 2. A person of skill in the art would know how to make and use a peptide with at least 95% identity to SEQ ID NO: 2. The ability to make and use altered amino acid sequences that fall within this identity range was well known in the art at the time of filing. Moreover, the specification contemplates peptides with this level of sequence identity and provides examples of altered amino acid sequences (see SEQ ID NO: 15 and 13). One of skill in the art would understand that the amino acid alterations shown in SEQ ID NOs: 15 and 13 are not dependent upon their different lengths (313 aa and 610 aa respectively). Thus, one of skill in the art would clearly consider other sequence lengths incorporating the same alterations. As noted in previous responses, it is not a requirement to list every conceivable amino acid sequence in a patent specification.

Applicants respectfully request reconsideration and withdrawal of this rejection.

Rejection under 35 U.S.C. § 112, Second Paragraph

Claims 32, 33, 38, 53, 59 and 63-65 stand rejected under 35 U.S.C. § 112, second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter of the invention.

Applicants note, as explained above, that claim 32, upon which the remaining rejected claims depend, has been amended to delete the phrase "specific interaction with parkin." The claim recites "a peptide compound having an amino acid sequence of at least

Appl. No. 09/785,548  
Reply and Amendment dated April 18 2005  
Reply to Office Action of November 18, 2004

95% identity to the full length human PAP1 sequence of SEQ ID NO: 2." Applicants submit that the claim particularly points out and distinctly claims the subject matter of the invention.

Accordingly, applicants respectfully request reconsideration and withdrawal of this rejection.


The application is in condition for allowance. Timely notification of allowability is requested.

If there are any additional fees due with the filing of this document, including fees for the net addition of claims, applicants respectfully request that any and all fees be charged to Deposit Account No. 50-1129. If any extension of time request or any petition is required for the entry of this paper or any of the accompanying papers, applicants hereby petition or request the extension necessary. The undersigned authorizes any fee payment from Deposit Account No. 50-1129.

Respectfully submitted,  
**Wiley Rein & Fielding LLP**

Date: April 18, 2005

By:

  
David J. Kulik  
Reg. No. 36,576

**WILEY REIN & FIELDING LLP**  
Attn: Patent Administration  
1776 K Street, N.W.  
Washington, D.C. 20006  
**Telephone: 202.719.7000**  
**Facsimile: 202.719.7049**